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Epstein–Barr virus latent membrane protein 1 (LMP1) activates NF-jB signaling pathways through
two C-terminal regions, CTAR1 and CTAR2. Previous studies have demonstrated that BS69, a multi-
domain cellular protein, regulates LMP1/CTAR2-mediated NF-jB activation by interfering with the
complex formation between TRADD and LMP1/CTAR2. Here, we found that BS69 directly interacted
with the LMP1/CTAR1 domain and regulated LMP1/CTAR1-mediated NF-jB activation and subse-
quent IL-6 production. Regarding the mechanisms involved, we found that BS69 directly interacted
with TRAF3, a negative regulator of NF-jB activation. Furthermore, small-interfering RNA-mediated
knockdown experiments revealed that TRAF3 was involved in the BS69-mediated suppression of
LMP1/CTAR1-induced NF-jB activation.
Structured summary:
MINT-7556591: lmp1 (uniprotkb:P03230) physically interacts (MI:0915) with BS69 (uniprotkb:Q15326)
by anti tag coimmunoprecipitation (MI:0007)
MINT-7556646: TRAF6 (uniprotkb:Q9Y4K3) physically interacts (MI:0915) with BS69 (uniprotkb:Q15326)
by anti tag coimmunoprecipitation (MI:0007)
MINT-7556658, MINT-7556670: TRAF3 (uniprotkb:Q13114) physically interacts (MI:0915) with BS69 (uni-
protkb:Q15326) by anti tag coimmunoprecipitation (MI:0007)
MINT-7556607: TRAF1 (uniprotkb:Q13077) physically interacts (MI:0915) with BS69 (uniprotkb:Q15326)
by anti tag coimmunoprecipitation (MI:0007)
MINT-7556634: TRAF5 (uniprotkb:O00463) physically interacts (MI:0915) with BS69 (uniprotkb:Q15326)
by anti tag coimmunoprecipitation (MI:0007)
MINT-7556622: TRAF2 (uniprotkb:Q12933) physically interacts (MI:0915) with BS69 (uniprotkb:Q15326)
by anti tag coimmunoprecipitation (MI:0007)
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Epstein–Barr virus (EBV) is strongly linked to the development of
multiplemalignancies, including post-transplant lymphoma, Hodg-
kin disease and nasopharyngeal carcinoma. EBV-encoded latent
membrane protein 1 (LMP1) is expressed in many EBV-associatedchemical Societies. Published by E
munology, Graduate School
-Ku Kita 12 Nishi 6, Sapporo
. Matsuda).tumor cells and is responsible for themajority of their altered cellu-
lar growth properties. Structurally, LMP1 is an integral membrane
protein of 386 amino acids (aa) that consists of a short cytoplasmic
N-terminal domain (aa 1–24), six transmembrane domains (aa 25–
186) and a long cytoplasmic C-terminal tail (aa 187–386) [1–3].
The cytoplasmic C-terminal tail contains two C-terminal activation
regions (CTARs), CTAR1 and CTAR2 [1,4]. Signals through these
two CTAR domains have been reported to induce p100 and p105
NF-jB precursors and generate p52 and p50 subunits, respectively
[5,6], indicating that LMP1 is involved in both canonical and non-
canonical activation of NF-jB pathways. CTAR1 contains a tumorlsevier B.V. All rights reserved.
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motif, and can bind to TRAF1, TRAF2, TRAF3 and TRAF5 [1,7–10].
CTAR2 interacts with TNFR-associated death domain protein
(TRADD), receptor-interacting protein (RIP) [11,12] and BS69 [13].
These CTAR1- and CTAR2-associated molecules have the ability to
induce or suppress LMP1-mediated NF-jB activation. Recently, we
identiﬁed STAP-2, an adaptor protein, as a new binding partner of
both CTAR1 and CTAR2, and demonstrated that STAP-2 negatively
regulates LMP1-mediated NF-jB activation [14].
BS69, a multidomain cellular protein containing PHD, Bromo,
PWWP and MYND domains, was originally identiﬁed as an adeno-
virus E1A-binding protein that inhibits the transactivation function
of E1A [15]. Furthermore, the C-terminal MYND domain of BS69
was shown to bind to the PXLXP motif existing in E1A, the EBV-en-
coded EBNA2 and the Myc-related cellular protein MGA [16].
Importantly, BS69 interacts with EBV-encoded LMP1 through its
MYND domain and acts as a scaffold protein in the LMP1-mediated
JNK pathway [13] by interacting with TRAF6. In addition, we previ-
ously reported that BS69 is able to negatively regulate LMP1-med-
iated NF-jB activation by displacing TRADD from the CTAR2
domain of LMP1 [17].
In the present study, we newly found that BS69 directly inter-
acts with the LMP1/CTAR1 domain and downregulates LMP1/
CTAR1-mediated NF-jB activation. We further found that TRAF3
directly interacts with BS69 and is involved in the BS69-mediated
suppression of LMP1/CTAR1-induced NF-jB activation. Taken to-
gether, BS69 is likely to act as an endogenous negative regulator
of both canonical and non-canonical NF-jB activation mediated
by LMP1.
2. Materials and methods
2.1. Reagents and antibodies
Expression vectors for BS69 and NF-jB-LUC were kindly pro-
vided by Shibuya (Tokyo Medical and Dental University, Tokyo, Ja-
pan) and Fujita (Kyoto University, Kyoto, Japan) [17–19]. Epitope-
tagged LMP1 and a series of TRAF constructs were described previ-
ously [14]. The following primary antibodies were obtained com-
mercially: anti-p52, anti-Bcl-2, anti-nucleoporin, anti-TRAF3 and
anti-Myc antibodies (Santa Cruz Biotechnology, Santa Cruz, CA);
anti-FLAG mAb (M2) and anti-HA antibody (Sigma–Aldrich, St.
Louis, MO); and anti-actin mAb (Chemicon International, Temecu-
la, CA).
2.2. Cell culture and transfection
A human cervix carcinoma cell line (HeLa), human embryonic
kidney carcinoma cell line (293T) were maintained in DMEM con-
taining 10% FCS. HeLa cells were transfected using jetPEI (PolyPlus-
transfection, Strasbourg, France) according to the manufacturer’s
instructions. 293T cells were transfected using a standard calcium
precipitation protocol [19]. A human B-lymphoblastoid EBV-trans-
formed cell line (SKW6-CL4) was maintained in RPMI1640 contain-
ing 10% FCS.
2.3. Transfection of small-interfering RNAs (siRNAs) and luciferase
assays
The siRNAs targeting human BS69 (#1 and #2) used in this
study were as follows: BS69 (#1), 50-GGAUGAAGUCGGACCACA-
ATT-30; BS69 (#2), 50-GAAGUUAUGAAGAGUUCAATT-30; TRAF3,
50-GGAAGAUUCGCGACUACAATT-30. HeLa cells were plated on
24-well plates at 2  104 cells/well and incubated with an siRNA
(15 pM) – Lipofectamine 2000 (Invitrogen, Carlsbad, CA) mixture
at 37 C for 4 h, followed by the addition of fresh medium contain-ing 10% FCS. HeLa cells were further transfected with or without
NF-jB-LUC with or without LMP1 using jetPEI as described in the
section above. At 24 h after transfection, the cells were harvested
and assayed for their luciferase activities using a Dual-Luciferase
Reporter Assay System (Promega, Madison, WI) according to the
manufacturer’s instructions. 293T cells were transfected as de-
scribed in the section above. The cells were harvested at 36 h after
transfection, lysed in 50 ll of Reporter Lysis Buffer (Promega) and
assayed for their luciferase and b-galactosidase activities according
to the manufacturer’s instructions. Three or more independent
experiments were carried out for each assay. Human SKW6-CL4
B cells were transfected with a control siRNA or BS69 siRNA (#2)
(100 pM) using a MicroPorator according to the manufacturer’s
instructions.
2.4. Immunoprecipitation and immunoblotting
Immunoprecipitation and western blotting assays were per-
formed as described previously [20]. The immunoprecipitates from
cell lysates were resolved by SDS–PAGE and transferred to PVDF
membranes (PerkinElmer, Boston, MA). The membranes were then
immunoblotted with the different primary antibodies. Immunore-
active proteins were visualized using an enhanced chemilumines-
cence detection system (Millipore, Bedford, MA).
2.5. RNA isolation, RT-PCR and quantitative real-time PCR
After cell harvesting, total RNA samples were extracted using
Iso-Gen (Nippon Gene, Tokyo, Japan) and subjected to RT-PCR
using an RT-PCR High-Plus-Kit (TOYOBO, Tokyo, Japan) [14]. Prim-
ers used for RT-PCR were: BS69: 50-GGATATTGGTTGCCAGGAGA-30
(sense), 50-GTGCCCATCTCCTGTTTGTT-30 (antisense), interleukin
(IL)-6: 50-ATGAACTCCTTCTCCACAAGCGC-30 (sense), 50-GAAGAA-
GCCCTCAGGCTGGACTG-30 (antisense), NF-jB2: 50-GGGTGTCCTG-
CATGTGACTA-30 (sense), 50-AGGGAGAAGGAGCCATCACT-30 (anti-
sense). Quantitative real-time PCR analyses for IL-6, BS69 and con-
trol G3PDH mRNA transcripts were carried out using Assays-on-
Demand™ gene-speciﬁc ﬂuorescently-labeled TaqMan MGB
probes in an ABI Prism 7000 sequence detection system (Applied
Biosystems, Foster City, CA).
2.6. Measurement of IL-6 in the culture supernatants
Concentrations of IL-6 in culture supernatants from siRNA-
transfected HeLa cells were measured by enzyme-linked immuno-
sorbent assay (ELISA) according to manufacturer’s instructions
(Biosource, Camarillo, USA).3. Results and discussion
3.1. BS69 interacts with the LMP1/CTAR1 domain and negatively
regulates LMP1/CTAR1-induced NF-jB activation
We previously showed that BS69 suppresses LMP1-induced
canonical NF-jB activation, which is mediated through the cyto-
plasmic C-terminal CTAR2 domain of LMP1 [17]. Although BS69
has been believed to bind to the CTAR2 domain, the yeast two-
hybrid assays employed the cytoplasmic carboxyl tail of LMP1
(aa 187–386), containing both CTAR1 and CTAR2, as bait [13].
These facts led us to investigate whether BS69 physically and
functionally interacts with the LMP1/CTAR1 domain, another
functional domain for NF-jB activation. First, we examined
whether BS69 binds to a truncated LMP1 (aa 1–231) lacking the
CTAR2 domain. Co-immunoprecipitation experiments were per-
formed using 293T cells transfected with expression vectors for
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(WT), LMP1 (aa 1–231) or empty vector. The immunoprecipitates
for LMP1 WT contained BS69 protein (Fig. 1A and B), as expected
from previous data [13,17]. Similarly, the immunoprecipitates for
LMP1 (aa 1–231) contained BS69 protein, indicating that BS69
was still able to associate with LMP1 in the absence of the CTAR2
domain in 293T cells.
Next, we investigated the effects of BS69 on LMP1/CTAR1-in-
duced NF-jB activation using transient reporter assays with NF-
jB-LUC. The NF-jB-LUC activities were induced by the expression
of LMP1 (aa 1–231) in 293T and HeLa cells (Fig. 1C), although NF-
jB activation induced by LMP1 (aa 1–231) was lower than LMP1
WT. Indeed, LMP1 WT showed approximately 2–3-fold higher acti-
vation than LMP1 (aa 1–231), when cells were transfected with the
same amount of plasmids (data not shown). Importantly, theseFig. 1. BS69 negatively regulates LMP1/CTAR1-induced NF-jB activation. (A) Schematic
293T cells (1  107) were transfected with HA-tagged BS69 (10 lg) with or without FLAG
the cells were lysed, immunoprecipitated with an anti-FLAG antibody and immunoblotted
with the anti-HA antibody. The asterisks indicate degraded protein bands derived from LM
231) (100 ng) and NF-jB-LUC (100 ng) and/or increasing amounts of HA-tagged BS69 (1
assayed for their luciferase activities using a Dual-Luciferase Reporter Assay System. An a
HA, anti-FLAG or anti-actin antibody. (D) HeLa cells in 24-well plates were transfected
transfection, total RNA samples isolated from these cells were subjected to RT-PCR analy
and quantitative real-time PCR analysis. Data represent the levels of BS69 mRNA normali
value at time zero. Data represent the means of duplicate PCR determinations, which gene
siRNA or BS69 siRNAs (#1 and #2) (15 pM). The cells were then transfected with FLAG-t
transfection, the cells were harvested and the luciferase activities were measured. At l
aliquot of each total cell lysate (TCL) was analyzed by immunoblotting with an anti-FLALMP1/CTAR1-induced NF-jB-LUC activities were signiﬁcantly re-
duced by co-expression of BS69 in a dose-dependent manner, sug-
gesting that BS69 negatively regulates LMP1/CTAR1-induced NF-
jB activation. This inhibitory effect of BS69 was conﬁrmed by
experiments using siRNAs that reduced the endogenous expression
of BS69 in HeLa cells. HeLa cells were transfected with speciﬁc siR-
NAs for BS69 (#1 and #2) or a control siRNA. Total RNA isolated
from the transfected cells was subjected to RT-PCR and quantita-
tive real-time PCR analysis, which conﬁrmed a reduction in BS69
mRNA expression (Fig. 1D). We then investigated the effects of
the BS69 siRNAs on LMP1/CTAR1-induced NF-jB activation. As
shown in Fig. 1E, siRNA-mediated reduced expression of BS69 re-
sulted in a signiﬁcant enhancement of the LMP1 (aa 1–231)-in-
duced NF-jB-LUC activities in these cells. Of importance, NF-jB-
LUC activation in the BS69 siRNA-treated HeLa cells was slightlydiagrams of the domain structures of LMP1 and a deletion mutant (aa 1–231). (B)
-tagged LMP1WT or a deletion mutant (aa 1–231) (10 lg). At 48 h after transfection,
with an anti-HA or anti-FLAG antibody. An aliquot of each TCL was immunoblotted
P1. (C) HeLa cells in 24-well plates were transfected with FLAG-tagged LMP1 (aa 1–
50 or 300 ng) using jetPEI. At 48 h after transfection, the cells were harvested and
liquot of each total cell lysate (TCL) was analyzed by immunoblotting with an anti-
with a control siRNA or siRNAs targeting BS69 (#1 and #2) (15 pM). At 48 h after
sis usingBS69 or G3PDH primers. The BS69 expression levels were quantiﬁed by RT
zed by that of G3PDH mRNA as an internal control and are expressed relative to the
rally varied by <10%. (E) HeLa cells in 24-well plates were transfected with a control
agged LMP1 (aa 1–231) (100 ng) and NF-jB-LUC (100 ng) using jetPEI. At 48 h after
east three independent experiments were carried out for each assay. *P < 0.01. An
G antibody.
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the possibility that endogenous BS69 regulates basal NF-jB activa-
tion by interacting with some unknown NF-jB activators. At the
present time, we do not know the mechanisms of regulation of ba-
sal NF-jB activation by BS69. Further detailed study will be re-
quired to clarify this issue.
NF-jB activation induces the production of inﬂammatory cyto-
kines, such as IL-6. To conﬁrm the regulation of LMP1/CTAR1-in-
duced NF-jB activation by BS69, LMP1/CTAR1-induced IL-6
mRNA expression was analyzed in the BS69 siRNA-treated HeLa
cells. LMP1 (aa 1–231)-induced IL-6 mRNA expression was aug-
mented in parallel with the decrease in BS69 (Fig. 2A). LMP1 (aa
1–231)-induced synthesis of IL-6 protein was also enhanced in
BS69 siRNA-transfected HeLa cells (Fig. 2B). Taking these resultsFig. 2. Reduction of endogenous BS69 enhances LMP1/CTAR1-induced IL-6 production an
transfected with a control siRNA or BS69 siRNAs (#2) (20 pM). The cells were then tra
transfection, total RNA samples were extracted and analyzed for their IL-6 mRNA express
IL-6 mRNA normalized by that of G3PDH mRNA as an internal control and are expre
mean ± SEM of triplicate cultures from three different experiments. *P < 0.01. An aliquot
HeLa cells in 12-well plates were transfected with a control siRNA or BS69 siRNAs (#2) (
using jetPEI. At 48 h after transfection, the culture supernatants were analyzed for IL-6 w
experiments. *P < 0.01. (C) HeLa cells in 12-well plates were transfected with a control s
LMP1 (1.5 lg) using jetPEI. At 48 h after transfection, the cells were lysed and fractionated
with anti-p52, anti-actin or anti-nucleoporin antibodies. (D) Human SKW6CL-4 B cells (1
MicroPorator according to the manufacturer’s instructions. The siRNA-transfected SKW6
was analyzed by immunoblotting with the indicated antibodies. Total RNA samples w
analysis.together, BS69 acts as a negative regulator of LMP1/CTAR1-induced
cytokine expression by interfering with NF-jB activation.
Next, we examined the effects of BS69 on LMP1-induced p100/
NF-jB2 processing to p52, which leads to non-canonical NF-jB
activation through the CTAR1 domain of LMP1 [6,21–23]. As shown
in Fig. 2C, siRNA-mediated reduced expression of BS69 resulted in
a signiﬁcant enhancement of LMP1-induced p100/NF-jB2 process-
ing to p52 in the nucleus of these cells. Therefore, BS69 regulates
the non-canonical NF-jB activation mediated by the CTAR1 do-
main of LMP1. We also tested the effect of BS69 knockdown in hu-
man EBV-positive SKW6-CL4 B cells. Importantly, reduction of
endogenous BS69 in SKW6-CL4 cells enhanced p100/NF-jB2 pro-
cessing into p52 via the non-canonical pathway and the Bcl-2 con-
tent (Fig. 2D). These results indicate that BS69 may act as ad LMP1-induced non-canonical p52 processing. (A) HeLa cells in 12-well plates were
nsfected with FLAG-tagged LMP1 (aa 1–231aa) (1.5 lg) using jetPEI. At 48 h after
ion levels by RT and quantitative real-time PCR analysis. Data represent the levels of
ssed relative to control siRNA-treated samples without LMP1. All values are the
of each TCL was also analyzed by immunoblotting with an anti-FLAG antibody. (B)
20 pM). The cells were then transfected with FLAG-tagged LMP1 (aa 1–231) (1.5 lg)
ith ELISA. All values are the mean ± S.E.M. of triplicate cultures from three different
iRNA or BS69 siRNA (#2) (20 pM). The cells were then transfected with HA-tagged
into cytosol and nuclear fractions. An aliquot of both fractions were immunoblotted
 106) were transfected with a control siRNA or BS69 siRNA (#2) (100 pM) using a
CL-4 B cells were cultured for an additional 36 h and lysed. An aliquot of each TCL
ere also extracted and analyzed for the BS69 mRNA expression levels by RT-PCR
Fig. 3. TRAF3 is involved in BS69-medtated suppression of LMP1/CTAR1-induced NF-jB activation. (A) 293T cells (1  107) were transfected with HA-tagged BS69 (10 lg)
with or without FLAG-tagged TRAF1, TRAF2, TRAF3, TRAF5 or TRAF6 (10 lg). At 48 h after transfection, the cells were lysed, immunoprecipitated with an anti-FLAG antibody
and immunoblotted with an anti-HA or anti-FLAG antibody. An aliquot of each TCL was immunoblotted with the anti-HA antibody. (B) HeLa cells in 24-well plates were
transfected with a series of TRAFs (30, 100 ng) together with FLAG-tagged LMP1 WT (100 ng) and NF-jB-LUC (100 ng) using jetPEI. At 48 h after transfection, the cells were
harvested and the luciferase activities were measured. At least three independent experiments were carried out for each assay. *P < 0.01. **P < 0.05. An aliquot of each total
cell lysate (TCL) was analyzed by immunoblotting with anti-FLAG or anti-actin antibodies. NS, non-speciﬁc band. (C) HeLa cells in 24-well plates were transfected with a
series of TRAFs (30, 100 ng) together with FLAG-tagged LMP1 (aa 1–231) (100 ng) and NF-jB-LUC (100 ng) using jetPEI. At 48 h after transfection, the cells were harvested
and the luciferase activities were measured. At least three independent experiments were carried out for each assay. *P < 0.01. **P < 0.05. An aliquot of each total cell lysate
(TCL) was analyzed by immunoblotting with anti-FLAG or anti-actin antibodies. NS, non-speciﬁc band. (D) HeLa cells in 24-well plates were transfected with a control siRNA
and/or BS69 siRNAs (#2) and/or TRAF3 siRNA (15 pM). The cells were then transfected with FLAG-tagged LMP1 (aa 1–231) (100 ng) and NF-jB-LUC (100 ng) using jetPEI. At
48 h after transfection, the cells were harvested and the luciferase activities were measured. At least three independent experiments were carried out for each assay. *P < 0.05.
An aliquot of each total cell lysate (TCL) was analyzed by immunoblotting with anti-FLAG, anti-TRAF3 or anti-actin antibodies. Total RNA samples were extracted and
analyzed for their BS69 mRNA expression levels by RT-PCR analysis.
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870 O. Ikeda et al. / FEBS Letters 584 (2010) 865–872modulator for non-canonical NF-jB activation in HeLa cells and
EBV-infected human B cells.
3.2. TRAF3 is involved in the BS69-mediated regulation of LMP1/
CTAR1-induced NF-jB activation
One of the important molecular mechanisms underlying LMP1-
induced NF-jB activation was investigated based on the fact that
LMP1/CTAR1 speciﬁcally interacts with TRAFs through a conserved
TRAF-binding motif [1,7–10]. TRAFs are important downstream
signaling adaptors for many receptors, such as the TNFR and IL-1
receptor/Toll-like receptor superfamilies, including CD40, and
function as docking molecules for proteins involved in TNFR signal-
ing, especially NF-jB signaling. Therefore, we tested the possible
associations of BS69 with a series of TRAFs. 293T cells were trans-Fig. 4. BS69 directly interacts with TRAF3. (A) Schematic diagrams of the domain structur
with HA-tagged BS69 (10 lg) with or without FLAG-tagged TRAF3 deletion mutants (10 l
HA antibody and immunoblotted with an anti-FLAG or anti-HA antibody. An aliquot of e
proposal of BS69 in the suppression of LMP1-induced NF-jB activation. LMP1 consists N-
which contains two NF-jB activating domain, CTAR1and CTAR2. BS69 directly interacts w
CTAR2. BS69 regulates CTAR1-medtated non-canonical NF-jB activation by interacting
from LMP1 (17). LMP1-induced JNK activation is mediated by BS69 and TRAF6 (13).fected with FLAG-tagged TRAF1, TRAF2, TRAF3, TRAF5 or TRAF6 to-
gether with HA-tagged BS69. Western blot analyses with an anti-
HA antibody revealed that BS69 physically interacted with all the
TRAFs examined (Fig. 3A).
We also examined the effects of TRAFs on LMP1WT- and LMP1/
CTAR1-induced NF-jB activation in HeLa cells. As shown in Fig. 3B
and C, TRAF3 showed a signiﬁcant suppressive effect on both
LMP1WT- and LMP1 (aa 1–231)-induced NF-jB activation,
although TRAF2 showed a small effect on LMP1 (aa 1–231)-in-
duced NF-jB activation. Furthermore, siRNA-mediated reduction
of TRAF3 expression resulted in enhanced LMP1 (aa 1–231)-in-
duced NF-jB activation (Fig. 3D), although siRNA-mediated reduc-
tion of TRAF2 expression did not enhance LMP1 (aa 1–231)-
induced NF-jB activation (data not shown). Therefore, we focused
on TRAF3 in regulation of LMP1/CTAR1-induced NF-jB activation.es of the TRAF3 deletion mutant fragments. (B) 293T cells (1  107) were transfected
g). At 48 h after transfection, the cells were lysed, immunoprecipitated with an anti-
ach TCL was immunoblotted with the anti-FLAG antibody. (C) Scheme of functional
terminal tail, six transmembrane domain and a long cytoplasmic C-terminal domain
ith LMP1 and suppresses LMP1-induced NF-jB activation through both CTAR1 and
with TRAF3, and CTAR2-mediated canonical NF-jB activation by displacing TRADD
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BS69 and TRAF3 in LMP1/CTAR1-induced NF-jB activation. HeLa
cells were transfected with speciﬁc siRNAs for BS69 or TRAF3, or
a control siRNA. Reductions in the expression of BS69 or TRAF3
(Fig. 3D) resulted in enhanced LMP1 (aa 1–231)-induced NF-jB
activation, indicating that both BS69 and TRAF3 are involved in
the regulation of LMP1/CTAR1-induced NF-jB activation in HeLa
cells. However, no synergistic effect was observed by combined
silencing of BS69 and TRAF3.
We further investigated which domains of TRAF3 mediated the
interactions with BS69. HA-tagged BS69 and the respective FLAG-
tagged TRAF3 mutants were transiently expressed in 293T cells.
Immunoprecipitation with an anti-HA antibody followed by wes-
tern blot analyses with an anti-FLAG antibody revealed that TRAF3
(D2–92), TRAF3 (D2–190), TRAF3 (D2–367) and TRAF3 (D422–
568) as well as TRAF3 WT were able to bind to BS69. However,
TRAF3 (D317–568) lost the ability to bind to BS69. These ﬁndings
suggested that the binding site for BS69 on TRAF3 was mapped to a
region (aa 368–421) in the N-terminal of the TRAF-binding domain
(Fig. 4B). With regard to domains of TRAF3 mediated the interac-
tions with LMP1/CTAR1, the C-terminal TRAF-binding domain of
TRAF3 was clearly essential although the results for the N-terminal
RING domain were complicated (data not shown). Therefore, these
data demonstrate that TRAF3 directly interacts with the LMP1/
CTAR1 and BS69.
Unlike many other TRAF family proteins that enhance NF-jB
activation, TRAF3 has been reported to suppress TNFR family-in-
duced NF-jB activation and was identiﬁed as a negative regulator
of NF-jB by promoting its degradation [24]. Moreover, recent stud-
ies have indicated that the B cells in TRAF3 knockout mice develop
splenomegaly and lymphadenopathy, in association with hyper-
globulinemia and autoimmunity, suggesting a role for TRAF3 in
B-cell homeostasis [25,26]. With regard to LMP1 signaling, experi-
ments involving TRAF3 overexpression have indicated that TRAF3
inhibits the NF-jB activation induced by LMP1. Furthermore,
TRAF3 has been shown to negatively regulate LMP1 signaling by
displacing TRAF1 and TRAF2 from CTAR1 [8]. In addition, TRAF3
is known to regulate LMP1 signaling through direct interactions
with CTAR1 and indirect interactions with CTAR2 [25]. Based on
the above information, we examined the effects of combined
knockdown of BS69 and TRAF3 on the LMP1/CTAR1-induced
NF-jB activation in HeLa cells. Interestingly, the reduction of
endogenous TRAF3 caused a signiﬁcant increase in LMP1 (aa 1–
231)-induced NF-jB activation but no signiﬁcant effect of BS69
siRNA-mediated enhancement of LMP1 (aa 1–231)-induced NF-
jB activation (Fig. 3D), indicating that BS69 fails to suppress
LMP1/CTAR1-induced NF-jB activation in the absence of TRAF3.
Therefore, a BS69–TRAF3 complex may interact with LMP1/CTAR1
and be responsible for the regulation of LMP1/CTAR1-induced NF-
jB activation. Taken together, these ﬁndings indicate that BS69
cooperates with TRAF3 in the regulation of LMP1/CTAR1-induced
NF-jB activation.4. Concluding remarks
In our previous study, we showed that BS69 suppresses
LMP1-induced NF-jB activation by competing with the complex
formation between TRADD and LMP1/CTAR2 [17]. Here, we have
demonstrated novel functions of BS69, namely that it interacts
with LMP1/CTAR1 and negatively regulates LMP1/CTAR1-medi-
ated NF-jB activation. Regarding the inhibitory mechanisms, we
found cooperative effects between BS69 and TRAF3. Therefore,
BS69 can inhibit LMP1-induced NF-jB activation mediated
through both the CTAR1 and CTAR2 domains. These suppressive
effects of BS69 may be similar to the case for STAP-2, which wepreviously reported as a negative regulator of LMP1/CTAR1- and
LMP1/CTAR2-induced NF-jB activation. However, the molecular
mechanisms underlying these effects are a little different. BS69
equally bound to all TRAF family proteins examined (TRAF1,
TRAF2, TRAF3, TRAF5 and TRAF6), while STAP-2 strongly inter-
acted with TRAF1 and TRAF3 [14]. The binding site for STAP-2
on TRAF3 was mapped to a narrow region (aa 317–367) between
a leucine-zipper domain and a TRAF-binding domain [14], while
the binding site for BS69 was mapped to a region (aa 368–421)
in the N-terminal portion of the TRAF-binding domain. Moreover,
LMP1 expression upregulated STAP-2 expression, suggesting that
STAP-2 plays a role in the defense of host cells against EBV after
infection. In contrast, BS69 is constitutively expressed and may
function in the defense of host cells against EBV under steady-
state conditions. Our proposed mechanisms for the actions of
BS69 on LMP1 signaling are illustrated in Fig. 4C. Our data sug-
gest that BS69 may be a novel candidate for antiviral therapies
aimed at regulating the EBV LMP1-induced NF-jB and JNK
pathways.Acknowledgements
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